Point72 Asset Management L.P. lessened its holdings in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 21.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 361,993 shares of the company's stock after selling 99,718 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.15% of BioNTech worth $42,994,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Planning Capital Management Corp raised its holdings in shares of BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after acquiring an additional 450 shares in the last quarter. Blue Trust Inc. grew its stake in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after purchasing an additional 388 shares during the period. EverSource Wealth Advisors LLC grew its stake in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock worth $43,000 after purchasing an additional 252 shares during the period. GAMMA Investing LLC grew its stake in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company's stock worth $41,000 after purchasing an additional 238 shares during the period. Finally, Clear Harbor Asset Management LLC purchased a new stake in BioNTech in the third quarter worth $210,000. Institutional investors own 15.52% of the company's stock.
BioNTech Stock Performance
BNTX stock traded up $4.14 during trading on Thursday, reaching $118.84. The stock had a trading volume of 678,438 shares, compared to its average volume of 812,013. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The stock's 50 day moving average is $113.81 and its two-hundred day moving average is $99.23. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market cap of $28.49 billion, a PE ratio of -56.59 and a beta of 0.22.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same quarter last year, the company earned $0.73 earnings per share. The business's revenue for the quarter was up 38.9% compared to the same quarter last year. As a group, equities analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on BNTX shares. TD Cowen cut their target price on BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a research note on Tuesday, November 5th. BMO Capital Markets reissued an "outperform" rating on shares of BioNTech in a research note on Monday. The Goldman Sachs Group raised BioNTech from a "neutral" rating to a "buy" rating and increased their target price for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Morgan Stanley raised BioNTech from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on BioNTech from $95.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, BioNTech presently has an average rating of "Moderate Buy" and a consensus price target of $138.67.
Get Our Latest Stock Report on BioNTech
About BioNTech
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
